M&A Deal Summary

Inotiv Acquires Protypia

On July 7, 2022, Inotiv acquired life science company Protypia

Acquisition Highlights
  • This is Inotiv’s 8th transaction in the Life Science sector.
  • This is Inotiv’s 9th transaction in the United States.
  • This is Inotiv’s 1st transaction in Tennessee.

M&A Deal Summary
Date 2022-07-07
Target Protypia
Sector Life Science
Buyer(s) Inotiv
Deal Type Add-on Acquisition

Target

Protypia

Nashville, Tennessee, United States
Protypia is an emerging protein/peptide bioanalytical company offering high-quality, targeted tissue-based protein and peptide mass spectrometry. Protypia is based in Nashville, Tennessee.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Inotiv

West Lafayette, Indiana, United States
Category Company
Founded 1974
Sector Life Science
Employees1,955
Revenue 572M USD (2023)
DESCRIPTION

Inotiv is a pharmaceutical development company providing contract research services and niche instrumentation, serving both the life sciences industries, primarily in drug research and development. Inotiv was founded in 1974 and is based in West Lafayette, Indiana.

DEAL STATS #
Overall 9 of 9
Sector (Life Science) 8 of 8
Type (Add-on Acquisition) 7 of 7
State (Tennessee) 1 of 1
Country (United States) 9 of 9
Year (2022) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-25 Histion

Everett, Washington, United States

Histion provides a histopathological evaluation of medical devices (including drug/device and biologic/device combinations), based in Everett, Washington.

Buy -
Mergr

Product

Company

Legal